Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02379377 · ClinicalTrials.gov registry record · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
A Phase 1 study of Cholangiocarcinoma and Resectable Hepatocellular Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT02379377: Recruiting Phase 1 study of Cholangiocarcinoma and Resectable Hepatocellular Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT02379377 is a Phase 1 study of Cholangiocarcinoma and Resectable Hepatocellular Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 110 participants, below the 384-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02379377, a Phase 1 study of Cholangiocarcinoma and Resectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
Primary Outcome
The Standardized Uptake Value (SUV) for 18F-FSPG PET images will be determined in the hepatocellular carcinoma (HCC) tumor lesions, non-HCC liver tumors (benign), and background liver (normal tissue). These metrics include SUVmax, SUVpeak, or SUVmean and are common PET imaging measures.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Fluorine F 18 L-glutamate Derivative 18F-FSPG
- BIOLOGICAL Carbon C 11 Acetate
- BIOLOGICAL Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
What NCT02379377 shows while recruiting
NCT02379377 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 384-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (71% lower).
The record links to 5 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT02379377 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02379377 about?
NCT02379377 is a clinical study titled "18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant". This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out h...
What is the current status of trial NCT02379377?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2022-02-15. Estimated completion is 2027-05-31.
What conditions does trial NCT02379377 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Resectable Hepatocellular Carcinoma, Benign Liver Tumor, Adult Hepatocellular Carcinoma, Metastases to Liver.
What interventions are being tested in trial NCT02379377?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Fluorine F 18 L-glutamate Derivative 18F-FSPG (BIOLOGICAL), Carbon C 11 Acetate (BIOLOGICAL), Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose (BIOLOGICAL).
Who is sponsoring clinical trial NCT02379377?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02379377 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02379377's enrollment target sits among peer trials
110 30th of 60 higher than 30 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study of MGC028 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- NCT03245411 · 110 participants · NA
Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI